Findings

What do systematic reviews say?

47 questions · 59 findings · 7 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 10.2%GRADE not reported 8 · 13.6%Very low 22 · 37.3%Low 17 · 28.8%Moderate 6 · 10.2%High 0 · 0%

Immediate‐release methylphenidate vs lithium

Efficacy (changes in symptoms of ADHD): participant‐rated ‐ not reported · adults with ADHD (available evidence for participants aged between 25 to 53 years old)

The review found no eligible studies for this question.

1 finding from 1 review

Immediate‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Osmotic‐release oral system methylphenidate vs placebo

Seizure frequency · people with ADHD and epilepsy

1 finding from 1 review

Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
Low

Osmotic‐release oral system methylphenidate vs placebo

Proportion of individuals withdrawing from treatment · people with ADHD and epilepsy

Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).

1 finding from 1 review

Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
RR 2.8 [1.14, 6.89]
1 study · 33 participants
Moderate

Osmotic‐release oral system methylphenidate vs placebo

Seizure severity · people with ADHD and epilepsy

1 finding from 1 review

Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
Low

Osmotic‐release oral system methylphenidate vs placebo

50% or greater reduction in seizure frequency · people with ADHD and epilepsy

The review found no eligible studies for this question.

1 finding from 1 review

Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Osmotic‐release oral system methylphenidate vs placebo

ADHD symptoms · people with ADHD and epilepsy

1 finding from 1 review

Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
Low

Osmotic‐release oral system methylphenidate vs placebo

Adverse drug events · people with ADHD and epilepsy

1 finding from 1 review

Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 33 participants
Moderate